Ataxia UK has been talking with Minoryx Therapeutics, a company focusing on developing new drugs for rare conditions, and we are delighted with this new trial being announced. The trial will be a phase 2 double blind placebo-controlled trial testing the effect of a drug called leriglitazone (MIN-102) a new selective PPAR gamma agonist in Friedreich’s ataxia pateints. See more information in the press release here.
UPDATE: The first patient was dosed at the end of April at the Hospital La Paz (Madrid) by a team headed up by Dr. Francisco Javier Rodríguez de Rivera. Additional sites, led by Prof. Alexandra Durr (ICM, Paris, France), Dr. Alexandra Darling (Hospital Sant Joan de Déu, Barcelona, Spain), Prof. Massimo Pandolfo (Hôpital Erasme-ULB, Brussels, Belgium), and Prof. Jörg Schulz (Universitätsklinikum RWTH, Aachen, Germany) are now also open for enrollment. View the press release for more information.